110 related articles for article (PubMed ID: 8917632)
1. Lymphoma-selective antibody Lym-1 recognizes a discontinuous epitope on the light chain of HLA-DR10.
Rose LM; Gunasekera AH; DeNardo SJ; DeNardo GL; Meares CF
Cancer Immunol Immunother; 1996 Sep; 43(1):26-30. PubMed ID: 8917632
[TBL] [Abstract][Full Text] [Related]
2. Recombinant expression of the beta-subunit of HLA-DR10 for the selection of novel lymphoma targeting molecules.
Albrecht H; Cosman M; Ngu-Schwemlein M; Corzett M; Curran KW; Dolan C; Fang X; DeNardo SJ; DeNardo GL; Balhorn R
Cancer Biother Radiopharm; 2007 Aug; 22(4):531-42. PubMed ID: 17803448
[TBL] [Abstract][Full Text] [Related]
3. Antilymphoma effects of anti-HLA-DR and CD20 monoclonal antibodies (Lym-1 and Rituximab) on human lymphoma cells.
Liu C; DeNardo G; Tobin E; DeNardo S
Cancer Biother Radiopharm; 2004 Oct; 19(5):545-61. PubMed ID: 15650447
[TBL] [Abstract][Full Text] [Related]
4. A selective high affinity ligand (SHAL) designed to bind to an over-expressed human antigen on non-Hodgkin's lymphoma also binds to canine B-cell lymphomas.
Balhorn RL; Skorupski KA; Hok S; Balhorn MC; Guerrero T; Rebhun RB
Vet Immunol Immunopathol; 2010 Oct; 137(3-4):235-42. PubMed ID: 20576295
[TBL] [Abstract][Full Text] [Related]
5. Internalization and shedding of Lym-1 monoclonal antibody following interaction with surface antigens of a cultured human B cell lymphoma.
Wang BS; Kelley KA; Lumanglas AL; Zimmer AM; Durr FE
Cell Immunol; 1989 Oct; 123(2):283-93. PubMed ID: 2790963
[TBL] [Abstract][Full Text] [Related]
6. Direct antilymphoma activity of novel, first-generation "antibody mimics" that bind HLA-DR10-positive non-Hodgkin's lymphoma cells.
West J; Perkins J; Hok S; Balhorn R; Lightstone FC; Cosman M; DeNardo SJ; DeNardo GL
Cancer Biother Radiopharm; 2006 Dec; 21(6):645-54. PubMed ID: 17257080
[TBL] [Abstract][Full Text] [Related]
7. Monoclonal Lym-1 antibody-dependent lysis of B-lymphoblastoid tumor targets by human complement and cytokinine-exposed mononuclear and neutrophilic polymorphonuclear leukocytes.
Ottonello L; Morone P; Dapino P; Dallegri F
Blood; 1996 Jun; 87(12):5171-8. PubMed ID: 8652830
[TBL] [Abstract][Full Text] [Related]
8. Potentiation of antiproliferative effects of monoclonal antibody Lym-1 and immunoconjugate Lym-1-gelonin on human Burkitt's lymphoma cells with gamma-interferon and tumor necrosis factor.
O'Boyle KP; Colletti D; Mazurek C; Wang Y; Ray SK; Diamond B; Rosenblum MG; Epstein AL; Shochat D; Dutcher JP
J Immunother Emphasis Tumor Immunol; 1995 Nov; 18(4):221-30. PubMed ID: 8680650
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic characterization in xenografted mice of a series of first-generation mimics for HLA-DR antibody, Lym-1, as carrier molecules to image and treat lymphoma.
DeNardo GL; Natarajan A; Hok S; Perkins J; Cosman M; DeNardo SJ; Lightstone FC; Mirick GR; Miers LA; Balhorn RL
J Nucl Med; 2007 Aug; 48(8):1338-47. PubMed ID: 17631545
[TBL] [Abstract][Full Text] [Related]
10. Nanomolecular HLA-DR10 antibody mimics: A potent system for molecular targeted therapy and imaging.
DeNardo GL; Natarajan A; Hok S; Mirick G; DeNardo SJ; Corzett M; Sysko V; Lehmann J; Beckett L; Balhorn R
Cancer Biother Radiopharm; 2008 Dec; 23(6):783-96. PubMed ID: 20443696
[TBL] [Abstract][Full Text] [Related]
11. Direct antilymphoma effects on human lymphoma cells of monotherapy and combination therapy with CD20 and HLA-DR antibodies and 90Y-labeled HLA-DR antibodies.
DeNardo GL; Tobin E; Chan K; Bradt BM; DeNardo SJ
Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7075s-7079s. PubMed ID: 16203805
[TBL] [Abstract][Full Text] [Related]
12. Lym-1-induced apoptosis of non-Hodgkin's lymphomas produces regression of transplanted tumors.
Zhang N; Khawli LA; Hu P; Epstein AL
Cancer Biother Radiopharm; 2007 Jun; 22(3):342-56. PubMed ID: 17651040
[TBL] [Abstract][Full Text] [Related]
13. Two new monoclonal antibodies, Lym-1 and Lym-2, reactive with human B-lymphocytes and derived tumors, with immunodiagnostic and immunotherapeutic potential.
Epstein AL; Marder RJ; Winter JN; Stathopoulos E; Chen FM; Parker JW; Taylor CR
Cancer Res; 1987 Feb; 47(3):830-40. PubMed ID: 3542194
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and radiolabeling of selective high-affinity ligands designed to target non-Hodgkin's lymphoma and leukemia.
Hok S; Natarajan A; Balhorn R; DeNardo SJ; DeNardo GL; Perkins J
Bioconjug Chem; 2007; 18(3):912-21. PubMed ID: 17373772
[TBL] [Abstract][Full Text] [Related]
15. Selective high-affinity ligand antibody mimics for cancer diagnosis and therapy: initial application to lymphoma/leukemia.
Balhorn R; Hok S; Burke PA; Lightstone FC; Cosman M; Zemla A; Mirick G; Perkins J; Natarajan A; Corzett M; DeNardo SJ; Albrecht H; Gregg JP; DeNardo GL
Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5621s-5628s. PubMed ID: 17875798
[TBL] [Abstract][Full Text] [Related]
16. Lym-1 Chimeric Antigen Receptor T Cells Exhibit Potent Anti-Tumor Effects against B-Cell Lymphoma.
Zheng L; Hu P; Wolfe B; Gonsalves C; Ren L; Khawli LA; Kaslow HR; Epstein AL
Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29261129
[TBL] [Abstract][Full Text] [Related]
17. A human-mouse chimeric Lym-1 monoclonal antibody with specificity for human lymphomas expressed in a baculovirus system.
Hu P; Glasky MS; Yun A; Alauddin MM; Hornick JL; Khawli LA; Epstein AL
Hum Antibodies Hybridomas; 1995; 6(2):57-67. PubMed ID: 7492752
[TBL] [Abstract][Full Text] [Related]
18. Characteristics of dimeric (bis) bidentate selective high affinity ligands as HLA-DR10 beta antibody mimics targeting non-Hodgkin's lymphoma.
DeNardo GL; Hok S; Van Natarajan A; Cosman M; DeNardo SJ; Lightstone FC; Mirick GR; Yuan A; Perkins J; Sysko VV; Lehmann J; Balhorn RL
Int J Oncol; 2007 Oct; 31(4):729-40. PubMed ID: 17786303
[TBL] [Abstract][Full Text] [Related]
19. New polymorphic HLA-DR epitopes recognized by three monoclonal antibodies produced against DR103 transfected L cells.
Cayrol C; Moro F; Sommer E; Tkaczuk J; Ohayon E; Cambon-Thomsen A
Tissue Antigens; 1992 Oct; 40(4):197-203. PubMed ID: 1281933
[TBL] [Abstract][Full Text] [Related]
20. A phase 1a clinical trial of LYM-1 monoclonal antibody serotherapy in patients with refractory B cell malignancies.
Hu E; Epstein AL; Naeve GS; Gill I; Martin S; Sherrod A; Nichols P; Chen D; Mazumder A; Levine AM
Hematol Oncol; 1989; 7(2):155-66. PubMed ID: 2784122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
